Main Menu

Publications Highlights View all by category

Types of Publications

Journal Articles

Nathan, P., Zweifel, M., Padhani, A.R., Koh, D.-., Ng, M., Collins, D.J., Harris, A., Carden, C., Smythe, J., Fisher, N., et al. (2012). Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin cancer res, Vol.18 (12), pp. 3428-3439.  show abstract

van der Graaf, W.T., Blay, J.-., Chawla, S.P., Kim, D.-., Bui-Nguyen, B., Casali, P.G., Schoffski, P., Aglietta, M., Staddon, A.P., Beppu, Y., et al. (2012). Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, Vol.379 (9829), pp. 1879-1886.

Pacey, S., Wilson, R.H., Walton, M., Eatock, M.M., Hardcastle, A., Zetterlund, A., Arkenau, H.-., Moreno-Farre, J., Banerji, U., Roels, B., et al. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin cancer res, Vol.17 (6), pp. 1561-1570.  show abstract

Olmos, D., Postel-Vinay, S., Molife, L.R., Okuno, S.H., Schuetze, S.M., Paccagnella, M.L., Batzel, G.N., Yin, D., Pritchard-Jones, K., Judson, I., et al. (2010). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet oncol, Vol.11 (2), pp. 129-135.  show abstract

Lee, C.P., Payne, G.S., Oregioni, A., Ruddle, R., Tan, S., Raynaud, F.I., Eaton, D., Campbell, M.J., Cross, K., Halbert, G., et al. (2009). A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br j cancer, Vol.101 (11), pp. 1860-1868.  show abstract

O'Donnell, A., Faivre, S., Burris, H.A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H.A., Hazell, K., Zoellner, U., Kovarik, J.M., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumours. J clin oncol, Vol.10 (26), pp. 1588-1595.


Pacey, S.C., Wilson, R.H., Walton, M., Martin, E., Moreno-Farre, J., Arkenau, H.T., Steinfeldt, H., Raynaud, F., Workman, P. & Judson, I., et al. (2007). A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors, MOL CANCER THER, Vol.6 (12), p.3332S.

In this section

Professional activities Publications